
Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc. (HEPA) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
hepa · pe ratio · data through Jun 9, 2026
Core PE Ratio Metrics
Trailing 12 months · TTMInsufficient PE history data (fewer than 3 valid fiscal years).
PE Ratio vs Peers
Biotechnology · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
Hepion Pharmaceuticals, Inc.You HEPA | $1M | N/A | — | — |
CDT Equity Inc. CDT | $4M | N/A | — | -$1177.90 |
Envoy Medical, Inc. COCH | $14M | N/A | — | -$1.21 |
Enveric Biosciences, Inc. ENVB | $1M | N/A | — | -$36.24 |
Lixte Biotechnology Holdings, Inc. LIXT | $86M | N/A | — | -$0.12 |
NewGenIvf Group Limited NIVF | $0M | 0.49x | -40.8% | $16.80 |
Petros Pharmaceuticals, Inc. PTPI | $0M | 1.17x | +40.8% | $0.01 |
Industry Average 2 peers with valid PE | — | 0.83x | baseline | — |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for Hepion Pharmaceuticals, Inc. (HEPA) measures how much investors pay for each dollar of the company's trailing earnings. HEPA's current PE ratio of N/A is calculated by dividing its stock price of $0.06 by its TTM earnings per share of —.
Frequently asked questions
HEPA pe ratio · 6 questionsHEPA's current PE ratio is N/A as of 2026-06-09, based on a stock price of $0.06 and TTM EPS of —. Data sourced from Financial Modeling Prep via HEPA's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · Hepion Pharmaceuticals, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-09